DDInter53 DDInter1676
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α, which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Alpelisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Alpelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glulisine
Alpelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Alpelisib {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Alpelisib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Alpelisib may lead to a major life threatening interaction when taken with Edoxaban